China Medical Device Regulatory Outsourcing

Mandatory in-country testing, the necessity for local legal representation, and the frequent updates to regulations and technical standards contribute to a highly intricate approval process. These requirements differ significantly from those in the U.S. or EU, making local expertise and assistance not just beneficial, but essential.

For medical device companies, this complexity emphasizes three critical priorities: accelerating time to market, ensuring full regulatory compliance, and controlling operational costs. Achieving all three internally is challenging, especially without a dedicated team on the ground in China. This is why outsourcing regulatory affairs to a specialist provider offers a strategic advantage.

Cisema assists international medical device companies with comprehensive regulatory affairs and compliance services specifically tailored to China. We help you register, launch, and maintain your products in full compliance with NMPA requirements, without the need to develop internal capabilities in China.

We function as your external regulatory department, managing every step from marketing authorizations to PMS. This allows you to stay compliant, competitive, and focused on your core business.

GMP Medical Devices
Outsourcing service

Benefits of Regulatory Affairs Outsourcing Services for China

Local Expertise with Global Integration

Cisema experts will guide you at every stage of product development, ensuring compliance, strategic alignment and a successful market entry. We facilitate interactions with regulatory agencies to streamline the approval process.  

Accelerated Access

By outsourcing regulatory tasks, companies can expedite approvals, seizing commercial opportunities more quickly and responding swiftly to demand.

Efficient

Eliminating the need for internal teams to manage complex regulations reduces overhead and enhances financial efficiency.

Concentration on Core Strengths

By delegating regulatory responsibilities, your internal teams can focus on innovation, production, and business growth, thereby boosting productivity.

Access to Specialized Knowledge

Partnering with an experienced regulatory outsourcing firm like Cisema grants you access to advanced regulatory strategies and technical expertise for efficient authorizations.

Enhanced Compliance & Risk Management

We assist in establishing robust quality systems, maintaining precise documentation, conducting audits, and ensuring adherence to NMPA standards — minimizing the risk of non-compliance.

Independent & Confidential Service

We operate solely on your behalf. As we are not a distributor, there is no conflict of interest, ensuring transparency and trust.

Our Regulatory Affairs Outsourcing Services

Our global presence, including offices in Europe, North America and Asia, allows us to provide a wide range of outsourcing services to medical device companies internationally. We understand the importance of regulatory compliance and quality management systems (QMS) for companies.

NMPA Approvals

Class I, II, and III medical devices
Local type testing, clinical evaluation, and dossier submission
Fast-track and innovative device pathways

Legal Agent & In-Country Representative

Act as your local agent with the NMPA
Maintain product licenses and regulatory compliance
Liaise with Chinese authorities on your behalf

Post-Market Surveillance

Adverse event reporting assistance
Change notifications and license renewals
UDI and tracking system support

Quality Management & Compliance

Compliance with Chinese GMP
Internal audits and documentation support
Risk management planning and implementation

Labeling & Packaging Compliance

Chinese Label and IFU review
UDI and barcode checks
Language and format verification

Regulatory Documentation & Control

Document control and quality system maintenance
Accurate, up-to-date documentation aligned with NMPA expectations

Training & Consultancy

Risk management and quality system training
Preparation for on-site inspections and supplier audits

Useful Articles

View More

Malaysia Drug–Medical Device Combination Products: A Guide to Classification & Regulatory Pathways

Learn how Malaysia classifies drug–medical device combination products and how the PMOA determines pathways and compliance responsibilities.

April 16, 2026
Malaysia Drug–Medical Device Combination Products: A Guide to Classification & Regulatory Pathways
Laboratory professional in protective eyewear, hair cover, sterile gown, and blue nitrile gloves examining a filled syringe in a clean laboratory environment.

Entering China’s Intraocular Lens (IOL) Market: NMPA Registration Requirements for Foreign Manufacturers

Understand the pathway for intraocular lens (IOL) registration in China, including NMPA requirements and key compliance steps.

April 15, 2026
Entering China’s Intraocular Lens (IOL) Market: NMPA Registration Requirements for Foreign Manufacturers
A close-up of an eye with a transparent intraocular lens held by surgical tweezers positioned in front of the pupil, illustrating ophthalmic medical device use. The visual supports themes of regulatory compliance, product registration, and market access

China Hyaluronic Acid Registration: A Complete Guide

A complete guide to China hyaluronic acid registration, covering classification, NMPA requirements, and compliance steps for manufacturers.

April 16, 2026
China Hyaluronic Acid Registration: A Complete Guide
China Hyaluronic Acid Registration: A Complete Guide

Indonesia's Halal Requirements for Medical Devices: What Manufacturers and Importers Need to Know

Learn which products are covered by Indonesia's halal framework, the labeling and manufacturing obligations, and phased compliance timelines.

April 15, 2026
Indonesia's Halal Requirements for Medical Devices: What Manufacturers and Importers Need to Know
Indonesia's Halal Requirements for Medical Devices: What Manufacturers and Importers Need to Know

Medical Device Registration in Indonesia: A Practical Guide for Foreign Manufacturers

Learn how to register medical devices in Indonesia, including Authorized Representative rules, classification, dossiers, timelines, and fees.

April 15, 2026
Medical Device Registration in Indonesia: A Practical Guide for Foreign Manufacturers
Medical Device Registration in Indonesia: A Practical Guide for Foreign Manufacturers

Medical Devices in China: A Regulatory Glossary for NMPA Compliance

Practical China medical device glossary explaining NMPA terms, with clear comparisons to US FDA and EU MDR terminology.

April 15, 2026
Medical Devices in China: A Regulatory Glossary for NMPA Compliance
Medical Devices in China: A Regulatory Glossary for NMPA Compliance
Previous
Previous

Explore Related Services

Whether you’re just starting out or are a blue-chip, access our wide range of services and 
outsourcing solutions to help your business thrive.

China Medical Device Approvals

We guide you through every step of the China medical device registration and filing process. We take care of compliance with NMPA requirements, advising you on the optimal China entry pathway, and helping you through the whole process.

NMPA Legal Agent

We are your authorized representative in China, and fulfill your registrations and filings as well as ensuring compliance with quality and PMS requirements.

China Clinical Trials

You may be required to provide supplementary clinical data on Chinese patients or conduct a full clinical trial in China.Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.

NMPA Type Testing

Our on-site test engineers coordinate and supervise type tests of your medical devices in NMPA-accredited laboratories.

Drug Device Combination Products

We assist with the classification, authorization, and compliance of combination products in China, whether drug or device led.

China Medical Device Quality Compliance

We help you achieve and ensure ongoing compliance with Chinese requirements.Our experts prepare and assist you for official NMPA inspections.

Medical Device PMS & Vigilance

The NMPA is placing greater focus on PMS such as more in-China sampling inspections and regular standard changes.Our specialist PMS team means you stay up to date with the many aspects of compliance.

NMPA Clinical Evaluation Report

Clinical Evaluation Reports can avoid the need for a China clinical trial in some instances. Our experts can advise and prepare NMPA compliant CERs.

How We’ve Helped Clients with Our Expert Guidance

Read about how we work with clients to find solutions, bringing together deep industry knowledge with leading talent.

View More
April 18, 2026

China Manufacture License Renewal for Level A2 Pressure Vessels

How Cisema Supported Inox Torres Group, S.L. in Successfully Renewing its China Manufacture License (SELO) for Level A2 Pressure Vessels

The China Manufacture License (CML), also known as the SELO license, is a mandatory requirement for manufacturers of pressure equipment intended for the Chinese market. Inox Torres Group, S.L.’s manufacturing site produces high-pressure vessels falling under the Level A2 scope. This license ensures compliance with China’s stringent quality and safety regulations for special equipment.

The Challenge: Managing SELO Complexity for High-Risk Equipment

Renewing a SELO license for Level A2 pressure vessels required careful coordination across regulatory, technical, and cultural dimensions.

  • Navigating Regulatory Complexity
    Navigating the complex and evolving SELO regulatory framework, particularly for high-risk products under Level A2, required meticulous planning and real-time compliance updates.
  • Ensuring Audit Readiness
    Inox Torres Group, S.L. needed to ensure all documentation and procedures were fully up to date and to select an appropriate demo product that met inspection requirements.
  • Managing Inspector Expectations
    Success depended on understanding the unspoken cultural and procedural expectations of SELO inspectors, including hosting and on-site hospitality.

Our Solution: Full-Spectrum SELO Audit Support

Recognizing the high stakes of SELO license renewal, Inox Torres Group, S.L. engaged Cisema for comprehensive regulatory and strategic support.

  • Reviewed the Quality Management System
    Cisema led the review and upgrade of the customer’s quality management system in line with the latest Chinese requirements, including a comprehensive gap analysis and revision of key documentation.
  • Audit Simulation & Preparation
    A preparatory remote audit simulation was conducted, walking through every step of the audit to ensure full readiness ahead of the on-site inspection.
  • Delivered On-Site Bilingual & Regulatory Support
    During the on-site audit, Cisema provided continuous bilingual support, interpreting inspector questions in real time and translating regulatory nuances for the customer.
  • Provided Culturally Appropriate Inspector Hosting
    Cisema arranged culturally appropriate corporate hospitality, helping establish a respectful and positive tone for the inspection. The team remained onsite throughout all audit days, including the weekend, to ensure no detail was overlooked.

The Outcome: Successful Renewal Without Disruption

Through hands-on execution and close coordination, the SELO renewal process was completed smoothly and efficiently.

  • Secured CML Renewal with Full A2 Status
    Inox Torres Group, S.L. successfully renewed its China Manufacture License for pressure vessels, maintaining its Level A2 classification.
  • Executed the Project Efficiently
    Full regulatory preparation and audit execution were completed within six months.
  • Achieved Seamless Inspector Coordination
    SELO inspectors were hosted and coordinated smoothly, with culturally aligned engagement throughout the audit.
  • Secured Regulatory Continuity  
    The renewal avoided operational disruptions and ensured compliance with updated SELO requirements.

Expertise and Efficiency: Acting as an Extension of the Client Team

Cisema’s experienced consultants acted as an extension of Inox Torres Group, S.L.’s regulatory and quality teams, providing both regulatory expertise and strategic foresight. Inspector concerns were anticipated and addressed proactively, transforming a potentially stressful process into a streamlined, well-orchestrated engagement with Chinese authorities.

Hands-on mentoring throughout the project helped the customer gain confidence and clarity in managing future SELO audits.

Why Choose Cisema

  • Strategic Regulatory Expertise: Deep understanding of Chinese bureaucracy, evolving SELO requirements, and inspector expectations.
  • Mentorship & Training: Step-by-step guidance that supported the customer’s quality team throughout the process.
  • Corporate Hospitality Excellence: Culturally aligned hosting that supports successful audit outcomes in China.
  • Audit Readiness & Precision: Gap analysis, audit simulation, and documentation refinement to pass SELO reviews efficiently.
  • End-To-End Support: Full management of the audit process, from document revision to on-site interpretation.

Further Information

Explore Cisema’s China Special Equipment (SELO) Certification services.

Learn More
China Manufacture License Renewal for Level A2 Pressure Vessels
Previous
Previous

Latest Insights

View More

Malaysia Introduces New e-IFU & Digital Labelling Guidance for Medical Devices

Malaysia’s MDA publishes the 7th edition of guidance on medical device labelling, with new e-labelling, e-IFU, and accessibility requirements

April 17, 2026
Malaysia Introduces New e-IFU & Digital Labelling Guidance for Medical Devices
Two professionals in an office review documentation for a HealthScreen glucose monitor while examining a computer display showing a product label with model number, barcode, and QR code. One person points to the code on the screen as the other reads.

Vietnam Cuts Advertising Red Tape for Healthcare Products

Vietnam’s MoH recently published Circular drops several healthcare advertising regulations and streamlines requirements for many categories.

April 17, 2026
Vietnam Cuts Advertising Red Tape for Healthcare Products

China NMPA Issues 26 Medical Device Standards Affecting Orthopedics, IVDs, & Software

The 26 new medical device standards cover orthopedic implants, IVDs, active devices, and software risk management.

April 17, 2026
China NMPA Issues 26 Medical Device Standards Affecting Orthopedics, IVDs, & Software

China Mandates Full UDI Compliance for All Medical Devices by 2029

China’s NMPA mandates full UDI coverage for all medical devices by 2029, linking compliance to registration, reimbursement, and market access.

April 17, 2026
China Mandates Full UDI Compliance for All Medical Devices by 2029

China NMPA Clarifies Pre-Review for Innovative Device Clinical Trials

China’s NMPA issues new guidance on clinical trial protocol pre-review for innovative devices, impacting overseas fast-track approvals.

April 17, 2026
China NMPA Clarifies Pre-Review for Innovative Device Clinical Trials

China NMPA Releases 2025 Medical Device Registration Data Report

China NMPA’s 2025 report highlights growth in medical device approvals, including advanced imported devices.

April 17, 2026
China NMPA Releases 2025 Medical Device Registration Data Report
Previous
Previous

A Reliable Partner from Start to Finish

With over 20 years of experience and a proven track record, Cisema is trusted by startups and global medtech leaders alike to manage China regulatory affairs with efficiency and precision. Contact us today to discuss how we can support your China strategy.

Request Proposal